View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 11, 2020updated 12 Jul 2022 11:39am

Seres Therapeutics’ C difficile drug meets Phase III primary goal

Seres Therapeutics has reported positive top-line data from the Phase III ECOSPOR III clinical trial of SER-109 to treat recurrent C difficile infection (CDI).

Seres Therapeutics has reported positive top-line data from the Phase III ECOSPOR III clinical trial of SER-109 to treat recurrent C difficile infection (CDI).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The study met the primary endpoint, demonstrating a statistically significant absolute reduction of 30.2% in the proportion of patients who had a recurrence in CDI within eight weeks of SER-109 administration compared to placebo.

Data showed that 11.1% of participants on SER-109 experienced a CDI recurrence versus 41.3% of those on placebo.

The company expects the efficacy data to support a biologics licence application (BLA) to the US Food and Drug Administration (FDA).

The safety data from the trial was favourable, where the adverse event profile was comparable to that of placebo.

Seres Therapeutics president and CEO Eric Shaff said: “Based on our prior discussions with the FDA, we believe this trial should provide the efficacy basis for submitting an application for product approval.

“We look forward to meeting with the FDA as soon as possible to discuss the regulatory path forward with the goal of bringing SER-109 to patients as a first-in-class microbiome therapeutic.”

SER-109 is an investigational, oral, biologically-derived microbiome therapeutic intended to decrease CDI recurrence.

The multi-centre, randomised, placebo-controlled ECOSPOR III trial compared the drug candidate to placebo following standard of care antibiotic treatment in a total of 182 patients with multiply recurrent CDI.

The primary efficacy endpoint of the study was the proportion of subjects with recurrent CDI at up to week eight. Participants are analysed for CDI recurrence until 24 weeks post-treatment as a secondary endpoint.

A SER-109 open-label study is being performed at certain clinical sites that were part of the ECOSPOR III trial, with plans to expand the study to additional sites.

Data from the open-label study will contribute to the SER-109 safety database.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena